YOUR MONTHLY DIABETES DOWNLOAD
|
For Type 1s, Type 2s, Loved Ones & Healthcare Professionals | AUGUST 2025
|
|
|
Just When You Thought You Had Diabetes Figured Out…
In this issue we’re featuring a case study with a patient who “won” the diabetes lottery and has both type 1 and type 2, which shouldn’t be legal! We’re also shedding light on the connection between T1D and other autoimmune conditions, and we’re discussing the typical changes that can happen with T2D over time.
I had minor surgery recently and I set my HCL/AID system in exercise mode at bedtime the night before. I came cruising in the next day with a value of 145 mg/dL (flat all night long). I not only impressed the anesthesiologist, but also felt confident my glucose values during surgery were going to be fine!
|
|
|
YOUR MONTHLY DIABETES DOWNLOAD
|
For Type 1s, Type 2s, Loved Ones & Healthcare Professionals | AUGUST 2025
|
|
|
Just When You Thought You Had Diabetes Figured Out…
In this issue we’re featuring a case study with a patient who “won” the diabetes lottery and has both type 1 and type 2, which shouldn’t be legal! We’re also shedding light on the connection between T1D and other autoimmune conditions, and we’re discussing the typical changes that can happen with T2D over time.
I had minor surgery recently and I set my HCL/AID system in exercise mode at bedtime the night before. I came cruising in the next day with a value of 145 mg/dL (flat all night long). I not only impressed the anesthesiologist, but also felt confident my glucose values during surgery were going to be fine!
|
|
|
|
|
Case Study | Double Diabetes
Who knew diabetes was a double dipper? It doesn’t seem fair that anyone could end up with both type 1 and type 2 diabetes at the same time, but it can happen. Learn who’s most susceptible to this double diagnosis, which treatments are recommended, and how you can actually work the diagnosis to your advantage.
|
|
|
Case Study | Double Diabetes
|
|
Who knew diabetes was a double dipper? It doesn’t seem fair that anyone could end up with both type 1 and type 2 diabetes at the same time, but it can happen. Learn who’s most susceptible to this double diagnosis, which treatments are recommended, and how you can actually work the diagnosis to your advantage.
|
|
|
|
|
Type 1 Diabetes | Related Autoimmune Conditions
Type 1 diabetes doesn’t always travel solo – some people with T1D can have other autoimmune diseases as well. Learn which ones are the most common for people with type 1, along with treatment options and tips for living successfully with multiple conditions.
|
|
|
Type 1 Diabetes | Related Autoimmune Conditions
|
|
Type 1 diabetes doesn’t always travel solo – some people with T1D can have other autoimmune diseases as well. Learn which ones are the most common for people with type 1, along with treatment options and tips for living successfully with multiple conditions.
|
|
|
|
|
Type 2 Diabetes | Medications & Treatments
If you’ve ever been told you need more medication, a higher dose of medication, or insulin, it’s not because you failed at managing type 2 diabetes. Learn about the natural progression of T2D, and how the latest treatment therapies can reduce the risk of serious complications.
|
|
|
Type 2 Diabetes | Medications & Treatments
|
|
If you’ve ever been told you need more medication, a higher dose of medication, or insulin, it’s not because you failed at managing type 2 diabetes. Learn about the natural progression of T2D, and how the latest treatment therapies can reduce the risk of serious complications.
|
|
|
|
|
Mounjaro Shows Heart Benefits for People with Type 2 Diabetes
|
Trial Results | Type 2 Diabetes
Lilly just announced topline results of their long-awaited Cardiovascular Outcome Trial (CVOT) where tirzepatide (Mounjaro), a dual GLP-1/GIP agonist, demonstrated a reduction in death from cardiovascular disease including heart attacks and stroke. It was not compared to placebo like all other CVOTs, but it was uniquely put head-to-head against dulaglutide (Trulicity), a GLP-1 RA that had already shown positive cardiovascular benefits!
Tirzepatide also led to larger reductions in A1c, more significant weight loss, and a reduced progression of chronic kidney disease. The SURPASS-CVOT was over four years in the making, and recruited over 30,000 people from 30 countries. This data confirms the cardiovascular benefits expected from this dual agonist, along with improved glucose control, sustained weight loss, and obstructive sleep apnea (currently indicated for Zepbound).
|
|
|
Mounjaro Shows Heart Benefits for People with Type 2 Diabetes
|
Trial Results | Type 2 Diabetes
|
|
Lilly just announced topline results of their long-awaited Cardiovascular Outcome Trial (CVOT) where tirzepatide (Mounjaro), a dual GLP-1/GIP agonist, demonstrated a reduction in death from cardiovascular disease including heart attacks and stroke. It was not compared to placebo like all other CVOTs, but it was uniquely put head-to-head against dulaglutide (Trulicity), a GLP-1 RA that had already shown positive cardiovascular benefits!
Tirzepatide also led to larger reductions in A1c, more significant weight loss, and a reduced progression of chronic kidney disease. The SURPASS-CVOT was over four years in the making, and recruited over 30,000 people from 30 countries. This data confirms the cardiovascular benefits expected from this dual agonist, along with improved glucose control, sustained weight loss, and obstructive sleep apnea (currently indicated for Zepbound).
|
|
|
TCOYD Community Quote of the Month
|
"I have had type 1 for 14 years - diagnosed at age 66. I’ve been a huge fan of you and TCOYD for almost all of the 14 years I’ve had diabetes!!! You are always much more informative than any endo I’ve seen!!!"
|
TCOYD® is a 501(c)(3) nonprofit educational organization. Our vision is for all people with diabetes and their loved ones to have full access to proper education and therapy, in order to allow for the prevention, early detection, and aggressive management of diabetes and the complications of diabetes.
|
|
|
Please consider helping TCOYD® improve the lives of those living with diabetes by supporting our virtual educational programs. To learn more, click below.
|
|
|
|
HUGE SHOUTOUT TO OUR SUPPORTING COMPANIES!
|
|
|
|
HUGE SHOUTOUT TO OUR SUPPORTING COMPANIES!
|
|
|
|
